Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inclusion preparation of levosimendan and beta cyclodextrin

A β-cyclodextrin and cyclodextrin technology, which is applied in the field of anti-heart failure drug-β-cyclodextrin inclusion preparations, can solve problems such as poor effect, and achieve the effects of strong solubility, simple operation and good stability

Inactive Publication Date: 2005-11-02
王思清
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The levosimendan preparation that has been on the market is levosimendan-KollidonPF12 injection. However, the Chinese Pharmacopoeia 2000 edition does not include KollidonPF12 as a non-vascular excipient. It is reported that KollidonPF12 is not effective as a solubilizing and stabilizing agent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inclusion preparation of levosimendan and beta cyclodextrin
  • Inclusion preparation of levosimendan and beta cyclodextrin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Levosimendan 2.5 mg / ml, hydroxypropyl β-cyclodextrin 50 mg / ml, and ethanol for injection 5 ml were dissolved to obtain a solution for injection.

Embodiment 2

[0031] Levosimendan 2.5mg / ml, hydroxypropyl beta cyclodextrin 50mg / ml, citrate 2mg / ml, and ethanol for injection 5ml are dissolved to obtain a solution for injection.

Embodiment 3

[0033] Levosimendan 2.5 mg / ml, hydroxypropyl β-cyclodextrin 50 mg / ml, dissolved in 5 ml of ethanol for injection, filtered, and vacuum-dried to obtain levosimendan-hydroxypropyl β-cyclodextrin inclusion compound dry powder.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to one kind of heart failure resisting medicine, cyclodextrin or its derivative included preparation of levosimendan. The preparation has calcium-sensitive positive muscle medicine levosimendan as main component, and beta-cyclodextrin or its derivative, such as hydroxypropyl beta-cyclodextrin as including matter.

Description

Technical field: [0001] The invention relates to an anti-heart failure drug-beta-cyclodextrin inclusion preparation, in particular to a calcium-sensitive positive inotropic drug levosimendan as the main molecule and hydroxypropyl beta-cyclodextrin as the guest molecule. preparation. technical background: [0002] Levosimendan, chemical name [(4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono]malononitrile, Its structural formula is as follows: [0003] [0004] Levosimendan is a calcium-sensitizing myocardial inotrope mainly used in the treatment of congestive heart failure. Its preparation method is found in EP56556B1, WO97 / 35841, WO01 / 19334, WO98 / 01111, CN1470238A. Levosimendan is yellow powder crystal, slightly soluble in water, pKa is 6.26, solubility in phosphate buffer (pH7.4) is 0.4mg / ml, solubility in water at pH6 and pH2 is 0.03mg / ml and 0.02 respectively mg / ml; insoluble and easily degradable in water. The levosimendan preparation that has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/50
Inventor 王思清毛白杨
Owner 王思清
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com